Function of matrix IGF-1 in coupling bone resorption and formation

被引:114
作者
Crane, Janet L. [1 ,2 ]
Cao, Xu [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2014年 / 92卷 / 02期
关键词
IGF-1; Bone remodeling; Mesenchymal stem cell; TGF-beta; Coupling; GROWTH-FACTOR-I; MESENCHYMAL STEM-CELLS; UNLOADING INDUCES RESISTANCE; INSULIN-RECEPTOR SUBSTRATE-1; CHILDHOOD-CANCER SURVIVOR; FACTOR-BINDING-PROTEINS; LONG-TERM MORTALITY; ONSET GH DEFICIENCY; PARATHYROID-HORMONE; MINERAL DENSITY;
D O I
10.1007/s00109-013-1084-3
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Balancing bone resorption and formation is the quintessential component for the prevention of osteoporosis. Signals that determine the recruitment, replication, differentiation, function, and apoptosis of osteoblasts and osteoclasts direct bone remodeling and determine whether bone tissue is gained, lost, or balanced. Therefore, understanding the signaling pathways involved in the coupling process will help develop further targets for osteoporosis therapy, by blocking bone resorption or enhancing bone formation in a space- and time-dependent manner. Insulin-like growth factor type 1 (IGF-1) has long been known to play a role in bone strength. It is one of the most abundant substances in the bone matrix, circulates systemically and is secreted locally, and has a direct relationship with bone mineral density. Recent data has helped further our understanding of the direct role of IGF-1 signaling in coupling bone remodeling which will be discussed in this review. The bone marrow microenvironment plays a critical role in the fate of mesenchymal stem cells and hematopoietic stem cells and thus how IGF-1 interacts with other factors in the microenvironment are equally important. While previous clinical trials with IGF-1 administration have been unsuccessful at enhancing bone formation, advances in basic science studies have provided insight into further mechanisms that should be considered for future trials. Additional basic science studies dissecting the regulation and the function of matrix IGF-1 in modeling and remodeling will continue to provide further insight for future directions for anabolic therapies for osteoporosis.
引用
收藏
页码:107 / 115
页数:9
相关论文
共 126 条
[1]  
Agnusdei D, 2005, J Endocrinol Invest, V28, P32
[2]   Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts [J].
Akune, T ;
Ogata, N ;
Hoshi, K ;
Kubota, N ;
Terauchi, Y ;
Tobe, K ;
Takagi, H ;
Azuma, Y ;
Kadowaki, T ;
Nakamura, K ;
Kawaguchi, H .
JOURNAL OF CELL BIOLOGY, 2002, 159 (01) :147-156
[3]   High serum IGFBP-2 is predictive of increased bone turnover in aging men and women [J].
Amin, Shreyasee ;
Riggs, B. Lawrence ;
Melton, L. Joseph, III ;
Achenbach, Sara J. ;
Atkinson, Elizabeth J. ;
Khosla, Sundeep .
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (06) :799-807
[4]   TREATMENT OF OVARIECTOMIZED RATS WITH THE COMPLEX OF RHIGF-I/IGFBP-3 INCREASES CORTICAL AND CANCELLOUS BONE MASS AND IMPROVES STRUCTURE IN THE FEMORAL-NECK [J].
BAGI, CM ;
DELEON, E ;
BROMMAGE, R ;
ROSEN, D ;
SOMMER, A .
CALCIFIED TISSUE INTERNATIONAL, 1995, 57 (01) :40-46
[5]   TISSUE LOCALIZATION OF PERFUSED ENDOTHELIAL-CELL IGF BINDING-PROTEIN IS MARKEDLY ALTERED BY ASSOCIATION WITH IGF-I [J].
BAR, RS ;
BOES, M ;
DAKE, BL ;
SANDRA, A ;
BAYNE, M ;
CASCIERI, M ;
BOOTH, BA .
ENDOCRINOLOGY, 1990, 127 (06) :3243-3245
[6]   Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency - A randomized, placebo-controlled trial [J].
Baum, HBA ;
Biller, BMK ;
Finkelstein, JS ;
Cannistraro, KB ;
Oppenheim, DS ;
Schoenfeld, AD ;
Michel, TH ;
Wittink, H ;
Klibanski, A .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (11) :883-+
[7]   The complex of recombinant human insulin like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administration [J].
Bauss, F ;
Lang, K ;
Dony, C ;
Kling, L .
GROWTH HORMONE & IGF RESEARCH, 2001, 11 (01) :1-9
[8]   Long-Term Safety of Recombinant Human Growth Hormone in Children [J].
Bell, J. ;
Parker, K. L. ;
Swinford, R. D. ;
Hoffman, A. R. ;
Maneatis, T. ;
Lippe, B. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (01) :167-177
[9]   The skeletal structure of insulin-like growth factor I-deficient mice [J].
Bikle, D ;
Majumdar, S ;
Laib, A ;
Powell-Braxton, L ;
Rosen, C ;
Beamer, W ;
Nauman, E ;
Leary, C ;
Halloran, B .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (12) :2320-2329
[10]   Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone [J].
Bikle, DD ;
Sakata, T ;
Leary, C ;
Elalieh, H ;
Ginzinger, D ;
Rosen, CJ ;
Beamer, W ;
Majumdar, S ;
Halloran, BP .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (09) :1570-1578